Shares of Hims & Hers tumble 26% after FDA says semaglutide is no longer in shortage
Publishing timestamp: 2025-02-21 16:02:43
Summary
FDA resolves shortage of semaglutide injection products, impacting Hims & Hers Health stock. Hims & Hers offers compounded semaglutide as alternative to brand-name drugs, but FDA will start taking action against compounders for violations. Despite regulatory challenges, Hims & Hers continues to expand its offerings and acquisitions.
Sentiment: MIXED
Tickers: HIMS, NOVO.B-DK, NVO,
Keywords: health care industry, pharmaceuticals, pharmaceutical industry regulation, internet, breaking news: technology, hims & hers health inc, breaking news: business, novo nordisk a/s, business news, media, technology,